Hikma Pharmaceuticals PLC (HKMPF PINK) stock market data APIs
$27.606
0(0%)
as of July 17, 2025
Try our APIs with
free plan!
Hikma Pharmaceuticals PLC Financial Data Overview
Price chart is built with
Anychart
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Prev. Close
27.606
Open
27.606
High
27.606
Low
27.606
52 wk Range
22.1579-28.3996
Market Cap
6 113 M
P/E Ratio
17.2237
Shares Outstanding
220 M
Revenue
3 127 M
EPS
0.5345
Dividends (Yield)
0.0288
Beta
0.66
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Hikma Pharmaceuticals PLC data using free add-ons & libraries
Get Hikma Pharmaceuticals PLC Fundamental Data
Hikma Pharmaceuticals PLC Fundamental data includes:
- Net Revenue: 3 127 M
- EBITDA: 787 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hikma Pharmaceuticals PLC News
New
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today...
Trending tickers: Palantir, Boeing, UBS, WH Smith and Hikma Pharmaceuticals
Palantir (PLTR) Shares in software company Palantir (PLTR) were up 4.4% in pre-market trading on Monday morning, having fallen more than 10% in Friday's session. The stock is up nearly 73% year-to-d...
Hikma Pharmaceuticals to invest $1B by 2030 to expand US manufacturing, R&D
Hikma Pharmaceuticals USA (OTCPK:HKMPF [https://seekingalpha.com/symbol/HKMPF]) plans to invest $1 billion [https://seekingalpha.com/pr/20151120-hikma-pharmaceuticals-usa-announces-1-billion-of-new-us...
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need fo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
